Table 5. Patient characteristics and outcomes.

Patient	PVTT (15)	HVT (15)	Baseline AFP (ng/mL)	Index tumor size (mm)	Best mRECIST response†	PN	MVE	Post-treatment tumor-absorbed dose (Gy)	TTS (months)	TTR (months)
1	VP2	–	15.6	89	CR	Extensive	1	225	13.6	49.3
2	VP4	–	44.2	111	PR	Extensive	0	169	8	21.5
3	VP2	–	3,071	93	CR	CPN	0	304	5.8	–
4	VP3	–	1,032	50	PR	Extensive	1	186	4.2	–
5	VP2	–	3.4	32	SD	Partial	0	31	2.1	–
6	VP3	–	7.5	47	PR	Extensive	0	322	4.1	10.3
7	VP2	–	38.4	41	CR	CPN	0	394	7.8	–
8	VP1	VV2	72.2	42	CR	CPN	0	388	8.3	–
9	VP2	–	15.4	37	PR	Extensive	1	396	3.7	14
10	VP2	VV1	2.2	77	PR	Extensive	1	318	7.2	22.5
11	–	VV1	61	37	PR	CPN	0	515	6.2	7.4
				29	–	Partial	–	148	–	–
				34	–	Extensive	–	382	–	–
12	VP3	–	3.5	20	CR	CPN	0	1,131	14.6	–
13	–	–	16.7	26	PR	CPN	1	497	10.5	–
				56	–	Partial	–	340	–	–
14	–	–	12.5	150	PR	Partial	1	225	3.5	10.1
15	VP3	–	13.1	26	CR	CPN	0	293	9.7	–
				37	–	CPN	–	506	–	–
16	–	–	60	91	CR	Extensive	0	311	4.3	–
17	VP3	–	13.7	55	PR	Extensive	0	678	6.2	–
18	VP2	–	69.8	74	PR	Extensive	0	655	3.9	–

^†, best mRECIST response = best localized mRECIST response = localized mRECIST response prior to surgery. PVTT, portal vein tumoral thrombosis; HVT, hepatic vein thrombosis; AFP, alpha fetoprotein; mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PN, pathological necrosis; MVE, microvascular embolism; TTS, time to surgery; TTR, time to recurrence; CPN, complete pathological necrosis; VP1, tumor thrombus distal to the second-order branches of portal vein; VP2, invasion of the second-order branches of portal vein; VP3, thrombus in the first-order branches; VP4, tumor thrombus in main portal trunk or portal branch contralateral to primarily involved lobe (or both); VV1, tumor thrombus in a branch of the hepatic vein; VV2, tumor thrombus in the main trunk of the hepatic veins.